SaaS Metrics
Academic Publication KRAS inhibitors: resistance drivers and combinatorial strategies
AI Semantic Synergy Context
Connecting this academic literature to real-world market discussions and products.
KRAS inhibitors: resistance drivers and combinatorial strategies
No description provided.
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
The rise of drug resistance in cancer cells presents a formidable challenge in modern oncology, necessitating the exploration of innovative therapeutic strategies. This review investigates the late...
Computational insights on the molecular interplay between KRas (G12D mutation) and SOS1 modulated by the inhibitor BI-3406
Author summary Protein-protein interactions serve as the crucial cornerstone for constructing cellular signaling pathways. Drug design targeted at protein interaction interfaces has emerged as the ...
Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis
The regulatory roles of oncogenic KRAS in cell death pathways remain poorly understood. Here the authors report that KRAS induces a type I interferon response that primes pancreatic cancer cells fo...
Curcumin derivatives with 1,5-diaryl-3-oxo-1,4-pentadiene: novel dual-function lead compounds showing anticancer and MDR reversal effects
RSC Adv., 2026, 16,27194-27201DOI: 10.1039/D6RA02187E, Paper Open Access   This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.Qinglong Wang, Xiaofa...
Frequently Asked Questions (FAQ)
Curated market intelligence mapped to this research.
What is the core focus of the research titled 'KRAS inhibitors: resistance drivers and combinatorial strategies'?
This literature focuses on:
What other academic literature is closely related to 'KRAS inhibitors: resistance drivers and combinatorial strategies'?
Yes, highly correlated activity was mapped. An entry titled 'KRAS inhibitors: resistance drivers and combinatorial strategies' discusses this: No description provided.
Are there commercial applications of 'KRAS inhibitors: resistance drivers and combinatorial strategies' in market news publications?
Yes, highly correlated activity was mapped. An entry titled 'Computational insights on the molecular interplay between KRas (G12D mutation) and SOS1 modulated by the inhibitor BI-3406' discusses this: Author summary Protein-protein interactions serve as the crucial cornerstone for constructing cellular signaling pathways. Drug design targeted at ...
Cite this Market Intelligence Report
Reference our AI-mapped synergy between this research and the commercial market to instantly build authority.